Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy
Abstract Background Patients with coronavirus disease 2019 (COVID-19) who receive dialysis therapy develop more severe disease and have a poorer prognosis than patients who do not. Although various data on the treatment of patients not receiving dialysis therapy have been reported, clinical practice...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-04-01
|
| Series: | Renal Replacement Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41100-022-00405-8 |
| _version_ | 1818266861624623104 |
|---|---|
| author | Ayumi Yoshifuji Munekazu Ryuzaki Yuki Uehara Norio Ohmagari Toru Kawai Yoshihiko Kanno Kan Kikuchi Hiroshi Kon Ken Sakai Toshio Shinoda Yaoko Takano Junko Tanaka Kazuhiko Hora Yasushi Nakazawa Naoki Hasegawa Norio Hanafusa Fumihiko Hinoshita Keita Morikane Shu Wakino Hidetomo Nakamoto Yoshiaki Takemoto |
| author_facet | Ayumi Yoshifuji Munekazu Ryuzaki Yuki Uehara Norio Ohmagari Toru Kawai Yoshihiko Kanno Kan Kikuchi Hiroshi Kon Ken Sakai Toshio Shinoda Yaoko Takano Junko Tanaka Kazuhiko Hora Yasushi Nakazawa Naoki Hasegawa Norio Hanafusa Fumihiko Hinoshita Keita Morikane Shu Wakino Hidetomo Nakamoto Yoshiaki Takemoto |
| author_sort | Ayumi Yoshifuji |
| collection | DOAJ |
| description | Abstract Background Patients with coronavirus disease 2019 (COVID-19) who receive dialysis therapy develop more severe disease and have a poorer prognosis than patients who do not. Although various data on the treatment of patients not receiving dialysis therapy have been reported, clinical practice for patients on dialysis is challenging as data is limited. The Infection Control Committee of the Japanese Society for Dialysis Therapy decided to clarify the status of treatment in COVID-19 patients on dialysis. Methods A questionnaire survey of 105 centers that had treated at least five COVID-19 patients on dialysis was conducted in August 2021. Results Sixty-six centers (62.9%) responded to the questionnaire. Antivirals were administered in 27.7% of facilities treating mild disease (most patients received favipiravir) and 66.7% of facilities treating moderate disease (most patients with moderate or more severe conditions received remdesivir). Whether and how remdesivir is administered varies between centers. Steroids were initiated most frequently in moderate II disease (50.8%), while 43.1% of the facilities initiated steroids in mild or moderate I disease. The type of steroid, dose, and the duration of administration were generally consistent, with most facilities administering dexamethasone 6 mg orally or 6.6 mg intravenously for 10 days. Steroid pulse therapy was administered in 48.5% of the facilities, and tocilizumab was administered in 25.8% of the facilities, mainly to patients on ventilators or equivalent medications, or to the cases of exacerbations. Furthermore, some facilities used a polymethylmethacrylate membrane during dialysis, nafamostat as an anticoagulant, and continuous hemodiafiltration in severe cases. There was limited experience of polymyxin B-immobilized fiber column-direct hemoperfusion and extracorporeal membrane oxygenation. The discharge criteria for patients receiving dialysis therapy were longer than those set by the Ministry of Health, Labor and Welfare in 22.7% of the facilities. Conclusions Our survey revealed a variety of treatment practices in each facility. Further evidence and innovations are required to improve the prognosis of patients with COVID-19 receiving dialysis therapy. |
| first_indexed | 2024-12-12T20:13:26Z |
| format | Article |
| id | doaj.art-e2a1db7a1164446ea2ec3f91a259b0e2 |
| institution | Directory Open Access Journal |
| issn | 2059-1381 |
| language | English |
| last_indexed | 2024-12-12T20:13:26Z |
| publishDate | 2022-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Renal Replacement Therapy |
| spelling | doaj.art-e2a1db7a1164446ea2ec3f91a259b0e22022-12-22T00:13:28ZengBMCRenal Replacement Therapy2059-13812022-04-01811910.1186/s41100-022-00405-8Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapyAyumi Yoshifuji0Munekazu Ryuzaki1Yuki Uehara2Norio Ohmagari3Toru Kawai4Yoshihiko Kanno5Kan Kikuchi6Hiroshi Kon7Ken Sakai8Toshio Shinoda9Yaoko Takano10Junko Tanaka11Kazuhiko Hora12Yasushi Nakazawa13Naoki Hasegawa14Norio Hanafusa15Fumihiko Hinoshita16Keita Morikane17Shu Wakino18Hidetomo Nakamoto19Yoshiaki Takemoto20Infection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyInfection Control Committee, The Japanese Society for Dialysis TherapyAbstract Background Patients with coronavirus disease 2019 (COVID-19) who receive dialysis therapy develop more severe disease and have a poorer prognosis than patients who do not. Although various data on the treatment of patients not receiving dialysis therapy have been reported, clinical practice for patients on dialysis is challenging as data is limited. The Infection Control Committee of the Japanese Society for Dialysis Therapy decided to clarify the status of treatment in COVID-19 patients on dialysis. Methods A questionnaire survey of 105 centers that had treated at least five COVID-19 patients on dialysis was conducted in August 2021. Results Sixty-six centers (62.9%) responded to the questionnaire. Antivirals were administered in 27.7% of facilities treating mild disease (most patients received favipiravir) and 66.7% of facilities treating moderate disease (most patients with moderate or more severe conditions received remdesivir). Whether and how remdesivir is administered varies between centers. Steroids were initiated most frequently in moderate II disease (50.8%), while 43.1% of the facilities initiated steroids in mild or moderate I disease. The type of steroid, dose, and the duration of administration were generally consistent, with most facilities administering dexamethasone 6 mg orally or 6.6 mg intravenously for 10 days. Steroid pulse therapy was administered in 48.5% of the facilities, and tocilizumab was administered in 25.8% of the facilities, mainly to patients on ventilators or equivalent medications, or to the cases of exacerbations. Furthermore, some facilities used a polymethylmethacrylate membrane during dialysis, nafamostat as an anticoagulant, and continuous hemodiafiltration in severe cases. There was limited experience of polymyxin B-immobilized fiber column-direct hemoperfusion and extracorporeal membrane oxygenation. The discharge criteria for patients receiving dialysis therapy were longer than those set by the Ministry of Health, Labor and Welfare in 22.7% of the facilities. Conclusions Our survey revealed a variety of treatment practices in each facility. Further evidence and innovations are required to improve the prognosis of patients with COVID-19 receiving dialysis therapy.https://doi.org/10.1186/s41100-022-00405-8Coronavirus disease 2019Renal replacement therapySteroidsDialysis |
| spellingShingle | Ayumi Yoshifuji Munekazu Ryuzaki Yuki Uehara Norio Ohmagari Toru Kawai Yoshihiko Kanno Kan Kikuchi Hiroshi Kon Ken Sakai Toshio Shinoda Yaoko Takano Junko Tanaka Kazuhiko Hora Yasushi Nakazawa Naoki Hasegawa Norio Hanafusa Fumihiko Hinoshita Keita Morikane Shu Wakino Hidetomo Nakamoto Yoshiaki Takemoto Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy Renal Replacement Therapy Coronavirus disease 2019 Renal replacement therapy Steroids Dialysis |
| title | Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy |
| title_full | Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy |
| title_fullStr | Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy |
| title_full_unstemmed | Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy |
| title_short | Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy |
| title_sort | committee report questionnaire survey on the treatment of covid 19 in patients receiving dialysis therapy |
| topic | Coronavirus disease 2019 Renal replacement therapy Steroids Dialysis |
| url | https://doi.org/10.1186/s41100-022-00405-8 |
| work_keys_str_mv | AT ayumiyoshifuji committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT munekazuryuzaki committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT yukiuehara committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT norioohmagari committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT torukawai committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT yoshihikokanno committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT kankikuchi committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT hiroshikon committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT kensakai committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT toshioshinoda committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT yaokotakano committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT junkotanaka committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT kazuhikohora committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT yasushinakazawa committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT naokihasegawa committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT noriohanafusa committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT fumihikohinoshita committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT keitamorikane committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT shuwakino committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT hidetomonakamoto committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy AT yoshiakitakemoto committeereportquestionnairesurveyonthetreatmentofcovid19inpatientsreceivingdialysistherapy |